Chronic kidney disease remains one of the world’s most urgent medical challenges. Despite advances in care, there are no curative therapies — current treatments only manage symptoms, leaving millions of patients at risk of progression to end-stage renal disease and dialysis and costing healthcare systems billions each year.
Our Approach
Our Approach
Chronic kidney disease remains one of the world’s most urgent medical challenges. Despite advances in care, there are no curative therapies — current treatments only manage symptoms, leaving millions of patients at risk of progression to end-stage renal disease and dialysis and costing healthcare systems billions each year.
A classic target with a novel mechanism of action and elegant modality-paired route of administration. By intervening upstream in disease biology, our technology has the potential to actually restore podocyte function and preserve renal health.
A platform for patient stratification leveraging biomarkers. We are developing tools to identify the patients most likely to benefit from specific interventions, laying the foundation for precision kidney medicine.
Kanjin Therapeutics is addressing this gap by developing first-in-class and best-in-class interventions:
Kanjin Therapeutics is addressing this gap by developing first-in-class and best-in-class interventions:
A platform for patient stratification leveraging biomarkers. We are developing tools to identify the patients most likely to benefit from specific interventions, laying the foundation for precision kidney medicine.
A classic target with a novel mechanism of action and elegant modality-paired route of administration. By intervening upstream in disease biology, our technology has the potential to actually restore podocyte function and preserve renal health.
Our approach is built on:
Novel target biology identified through cross-border academic collaborations.
Preclinical efficacy data demonstrating restoration of renal function in multiple disease models.
Clinical biomarker correlations supporting patient selection and translational potential.
Our lead program is focused on focal segmental glomerulosclerosis (FSGS), a devastating disease with limited treatment options. Additional indications are under exploration within the spectrum of chronic kidney disease.
Scientific Foundation
Pipeline Snapshot
Pipeline Snapshot
Our lead program is focused on focal segmental glomerulosclerosis (FSGS), a devastating disease with limited treatment options. Additional indications are under exploration within the spectrum of chronic kidney disease.
Scientific Foundation
Our approach is built on:
Novel target biology identified through cross-border academic collaborations.
Preclinical efficacy data demonstrating restoration of renal function in multiple disease models.
Clinical biomarker correlations supporting patient selection and translational potential.
